Home > Insider Trading > Sciclone Pharmaceuticals Inc

Sciclone Pharmaceuticals Inc (SCLN)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

1 - 10
Next >>

13D Filing: Gl Partners Capital Management Ltd and Sciclone Pharmaceuticals Inc (SCLN)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...

Keep Reading →

June 9th, 2017 - Hedge Funds

Hedge Funds Are Buying SciClone Pharmaceuticals, Inc. (SCLN)

Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required...

Keep Reading →

December 13th, 2016 - Hedge Funds News

Hedge Funds Aren't Crazy About SciClone Pharmaceuticals, Inc. (SCLN) Anymore

The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30.

Keep Reading →

November 27th, 2015 - Hedge Funds News

Here Is Why These Four Stocks Stand Out from the Crowd on Tuesday

All major U.S. stock indexes slide into negative territory in early trading on Tuesday, after having registered losses of over 1% on Monday.

Keep Reading →

November 10th, 2015 - Market Movers News

Should You Buy Surging SciClone Pharmaceuticals (SCLN), Up By 14.66% Today?

SciClone Pharmaceuticals Inc (NASDAQ:SCLN) is a $503.65 million market cap company which serves as a provider of therapies for oncology, infectious diseases and cardiovascular disorders in China, Hong...

Keep Reading →

July 1st, 2015 - Hedge Funds News

GL Partners Adds to Position in SciClone Pharmaceuticals; Reveals New Stake in China Biologic Products

GL Partners Capital Management has increased the holding of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) stock.

Keep Reading →

November 21st, 2013 - Hedge Funds News

Do Hedge Funds and Insiders Love SciClone Pharmaceuticals, Inc. (SCLN)?

In the 21st century investor’s toolkit, there are tons of indicators market participants can use to analyze stocks. A pair of the most innovative are hedge fund and insider trading interest.

Keep Reading →

September 5th, 2013 - News

Depomed Inc (DEPO): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?

In the eyes of many market players, hedge funds are viewed as delayed, outdated financial vehicles of an era lost to time.

Keep Reading →

September 3rd, 2013 - News

Is Sucampo Pharmaceuticals, Inc. (SCMP) Going to Burn These Hedge Funds?

According to most stock holders, hedge funds are perceived as slow, old financial tools of the past.

Keep Reading →

July 1st, 2013 - News

Pernix Therapeutics Holdings Inc (PTX): Are Hedge Funds Right About This Stock?

In the financial world, there are plenty of gauges market participants can use to track their holdings. A couple of the most underrated are hedge fund and insider trading activity.

Keep Reading →

July 1st, 2013 - News